Financial Data and Key Metrics Changes - Revenue for Q3 2022 was $50 million, down 3% year-over-year, with a decline of 4.2% sequentially from Q2 [11][30] - Adjusted net income was $1.7 million or $0.12 per fully diluted share, compared to $2.8 million or $0.20 per share in the prior year [35] - Gross margin decreased to 80.7% from 82.9% in the prior year, attributed to increased inventory obsolescence and elevated shipping expenses [34] Business Line Data and Key Metrics Changes - Revenue in the Americas declined 8.2% year-over-year to $33.4 million, driven by a 10.7% decrease in total active accounts [31] - Asia Pacific and Europe region revenue increased 9.3% to $16.6 million, supported by a 4.3% increase in total active accounts [32] Market Data and Key Metrics Changes - Internationally, total active accounts grew by 4.3%, with revenue increasing 9.3% or 17.3% when adjusted for foreign currency impact [11] - In Japan, revenue increased slightly by 0.1% on a constant currency basis, despite lower revenue attributed to foreign currency fluctuations [33] Company Strategy and Development Direction - The company is focused on three primary areas for growth: people, product, and customer experience [16] - A new product strategy has been introduced to enhance future product line growth, emphasizing the activation benefits of the flagship product, Protandim Nrf2 Synergizer [18] - The company is committed to a balanced approach between share repurchase and dividend payments to maximize shareholder value [76][78] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenging operating environment but expressed confidence in the company's long-term value creation strategy [9][41] - The introduction of a quarterly dividend of $0.03 per share reflects the company's commitment to enhancing shareholder value [10] Other Important Information - The company ended the quarter with $17.8 million in cash and no debt, maintaining a strong financial position [37] - A new event, Activate 2022, is planned to align distributors and promote growth strategies [28] Q&A Session Summary Question: Can you discuss the gross margins and inventory obsolescence? - Management noted that the decrease in gross margins was primarily due to inventory obsolescence related to the personal care product line and ongoing pressures on shipping and fulfillment costs [44][45] Question: What are the expectations for distributor growth in the Americas? - Management indicated that they believe they have bottomed out in distributor enrolments and are cautiously optimistic about future growth, supported by the MVP incentive program [54][55] Question: Can you elaborate on the scientific support for the products? - Management highlighted that Protandim Nrf2 Synergizer is backed by over 30 clinical studies and peer-reviewed research, emphasizing its effectiveness in reducing oxidative stress [59][60] Question: How does the company view competition in the market? - Management stated that there is no direct competition with the same patented technology and peer-reviewed studies as Nrf2, differentiating their products from general antioxidants [65][66] Question: What is the rationale behind introducing a quarterly dividend? - Management explained that the dividend is part of a balanced approach to maximize shareholder value, alongside ongoing share repurchase programs [76][78]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________________________________________ Form 10-Q ________________________________________________________________________________ ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO (Address of ...

LifeVantage Corporation (NASDAQ:LFVN) Q2 2022 Earnings Conference Call February 1, 2022 4:30 PM ET Company Participants Reed Anderson - ICR Steve Fife - Chief Executive Officer Carl Aure - Chief Financial Officer Conference Call Participants Doug Lane - Lane Research Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within the transcript are designed to help you navigate the audio should the corresponding text be unclear. The machine- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________________________________________ Form 10-Q ________________________________________________________________________________ ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commissi ...

Form 10-Q ________________________________________________________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Washington, D.C. 20549 ________________________________________________________________________________ FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commiss ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________________________________________________ FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended June 30, 2021 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from __________ to __________ Commission file number: 001-35647 ________________________________________ ...

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Washington, D.C. 20549 ________________________________________________________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Form 10-Q ________________________________________________________________________________ FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission ...

LifeVantage Corporation (NASDAQ:LFVN) Q2 2021 Earnings Conference Call February 2, 2021 4:30 PM ET Company Participants Reed Anderson - Investor Relations Garry Mauro - Chairman Justin Rose - Chief Sales & Marketing Officer Steve Fife - President, Interim Chief Executive Officer & Chief Financial Officer Conference Call Participants Doug Lane - Lane Research Operator Good day, ladies and gentlemen, thank you for standing by. Welcome to today's conference call to discuss LifeVantage's Second Fiscal Quarter o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________________________________________ Form 10-Q ________________________________________________________________________________ ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commissi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission file number 001-35647 ________________________________________________________________________________ LIFEVANTAGE CORPORATION (Exact name of Registrant as specified in its charter) ________________________________________________________________________________ Delaware 90-0224471 Washington, D.C. 20549 ________________________________________________________________________________ Form 10-Q _______________________________________________________ ...